Yuhan has secured 260 billion won in technology fee in 3 yrs

After the technology transfer, 4 additional technology fees were received

ince 2018, it has secured a total of $217.65 million in technology fees

Yuhan Corporation is creating a case of securing additional technology fees by advancing to the development stage even after exporting new drug technologies.

 

It has secured a total of 260 billion won in new drug technology exports over the past 3 years.

 

It has secured more money with additional technology fees than the down payment secured by exporting new drug technologies.

 

According to the industry on the 17th, Yuhan Corporation will receive $10 million milestone for entering phase 1 clinical trials of YH25724, NASH treatment transferred to Beringer Ingelheim.

 

YH25724 is a drug that Yuhan Corporation exported up to $870 million in technology to Beringer Ingelheim in July 2019.

 

Under the terms of the contract, the down payment that is not obliged to return is $40 million.

 

Yuhan Corporation received a total of $50 million in technology exports of YH25724.

 

Yuhan Corporation is achieving results in acquiring additional technology fees by advancing to the development stage of technology export tasks.

 

Yuhan Corporation has signed a total of five new drug technology export contracts since July 2018.

 

In July 2018, it transferred YH14618 technology to Spine Biopharma, a treatment for degenerative disc disease.

 

It received a down payment of $650,000 and was guaranteed $2175 million with step-by-step milestones based on development, permission and sales.

 

Yuhan Corporation launched Janssen Biotech's anticancer drug in November 2018.

 

Lazertinib' technology was exported.

 

The total contract size, including $50 million in down payment, which is not obligated to return, is up to $1.25 billion.

 

In January 2019, Gilead Science signed a license and joint development contract for new drug candidates acting on two drug targets for NASH treatment.

 

It is a condition that receives a down payment of $15 million and receives $777 million milestones according to development, permission and sales.

 

In August last year, it signed a technology transfer contract with Processa Pharmaceuticals in the United States for YH12852, a candidate for treating functional gastrointestinal diseases.

 

Yuhan Corporation received a down payment of $2 million as a stock that was not obliged to return.

 

Yuhan has secured additional technology fees four times due to progress in the development stage after exporting new drug technologies.

 

Yuhan Corporation received Lazertinib's milestone of $35 million from Janssen in April last year.

 

Janssen provided additional milestones to Yuhan Corporation at the time, starting clinical trials of combination therapy between Amivantamab and Lazertinib.

 

Yuhan Corporation received an additional $65 million in additional milestones in November last year when it began recruiting subjects for a phase 3 clinical trial of Janssen's own anticancer drug Amivantamab and Lazertinib.

 

YH25724, which Beringer Ingelheim started clinical trials this time, agreed to receive $10 million out of the $40 million down payment when the non-clinical toxicity test was completed, but received the remaining down payment last year.

 

As a result, Yuhan Corporation has secured $2176.5 million (about 260 billion won), including additional milestones over the past three years.

 

Of the technical fees received by Yuhan Corporation, milestones exceeded the down payment of $110 million.

 

The technology fees secured by Yuhan Corporation are contributing to improving its performance.

 

Yuhan Corporation has recognized technology fee profits for 11 consecutive quarters since the first quarter of 2019.

 

The cumulative technology fee revenue reflected for two years and nine months amounted to 217.3 billion won.